Category Archives: Deals

Pharm Exec’s Pharma Top 50 in Brief

The vigorous return of M&A activity this year brings us back to the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an endlessly restructuring healthcare system? Anecdotal evidence combined with some discomfiting statistics on pipeline productivity of the past 15 years suggests that the answer […]
Also posted in Strategy | Tagged , , , , | Leave a comment

The Rx Firm Tax Exodus: Is Something Wrong with the U.S. System?

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]
Also posted in Europe, Global, Guest Blog, Legal, Op-Ed, Strategy | Tagged , , , , , , | Leave a comment

Pharma Leads the Way in M&A

 The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal. The sector’s deals have been valued at US$252.5 bn,  a 16.9% market share in global M&A. Deal value is 48.2% above the whole of 2013’s value, and four deals account for a 61.3% share in the […]
Also posted in Europe, Global | Tagged , | Leave a comment

Big Biotech Gains Offset Big Pharma Losses

Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals. The report shows that when it comes to pharmaceutical industry jobs, Big Biotech and specialty drugmakers are growing in significance, more than offsetting the […]
Also posted in Biotech, Global, Strategy | Tagged , , , , , | Leave a comment

GSK's Tykerb "Little More" to Offer

The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival, says research and consulting firm GlobalData.
Also posted in healthcare, R&D | Tagged , , , , , | Leave a comment
  • Categories

  • Meta